Formulation Development and Clinical Manufacturing: Manufacture of TLC-ART101 Bulk Product for Clinical Trials

NIH RePORTER · NIH · N01 · $785,631 · view on reporter.nih.gov ↗

Abstract

The Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), maintains a portfolio of contracts to support the development of (1) therapies for HIV infection and its complications and coinfections, and (2) microbicides for preventing the sexual transmission of HIV. Services provided under this contract assist investigators in academic settings and small pharmaceutical firms in filling specific gaps in their drug development plan as they advance their product towards clinical investigation of therapies for HIV infection and interventions to prevent HIV transmission. Activities will include the development of formulations of potential therapeutic agents and microbicides. In addition studies will be conducted to assess the pharmacology and toxicology of potential therapeutic agents and microbicides.

Key facts

NIH application ID
10215314
Project number
272201400006I-0-759302000001-1
Recipient
SRI INTERNATIONAL
Principal Investigator
JON MIRSALIS
Activity code
N01
Funding institute
NIH
Fiscal year
2020
Award amount
$785,631
Award type
Project period
2020-07-15 → 2021-07-14